Literature DB >> 3048760

Circumsporozoite antibodies and falciparum malaria incidence in children living in a malaria endemic area.

L W Pang, N Limsomwong, J Karwacki, H K Webster.   

Abstract

In a case-control study we examined the association of Plasmodium falciparum circumsporozoite antibodies (anti-R32tet32) with subsequent P. falciparum infections. A study population of 140 children living in an endemic area was followed longitudinally for 25 weeks with weekly blood smears for malaria parasites and, once every two weeks, serum samples for circumsporozoite antibody determinations. From the malaria cases, antibody measurements occurring between two and six weeks prior to the onset of parasitaemia were utilized. For each case, two controls were selected. The results from 17 cases and 34 controls failed to show a statistically significant difference in antibody levels prior to the infection (P=0.07, one-tailed Student's t-test). However, 8 of the 17 cases had antibody present, indicating a level that was not protective against patent infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3048760      PMCID: PMC2491131     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  14 in total

1.  The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain).

Authors:  J ARNOLD; A S ALVING; R S HOCKWALD; C B CLAYMAN; R J DERN; E BEUTLER; C L FLANAGAN; G M JEFFERY
Journal:  J Lab Clin Med       Date:  1955-09

2.  Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine.

Authors:  J F Young; W T Hockmeyer; M Gross; W R Ballou; R A Wirtz; J H Trosper; R L Beaudoin; M R Hollingdale; L H Miller; C L Diggs
Journal:  Science       Date:  1985-05-24       Impact factor: 47.728

3.  Effects of pyrimethamine, chlorguanide, and primaquine against exoerythrocytic forms of a strain of chloroquine-resistant Plasmodium falciparum from Thailand.

Authors:  R D Powell; G J Brewer
Journal:  Am J Trop Med Hyg       Date:  1967-11       Impact factor: 2.345

4.  Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.

Authors:  W R Ballou; S L Hoffman; J A Sherwood; M R Hollingdale; F A Neva; W T Hockmeyer; D M Gordon; I Schneider; R A Wirtz; J F Young
Journal:  Lancet       Date:  1987-06-06       Impact factor: 79.321

5.  Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria.

Authors:  F Zavala; J P Tam; M R Hollingdale; A H Cochrane; I Quakyi; R S Nussenzweig; V Nussenzweig
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

6.  Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum.

Authors:  S L Hoffman; R Wistar; W R Ballou; M R Hollingdale; R A Wirtz; I Schneider; H A Marwoto; W T Hockmeyer
Journal:  N Engl J Med       Date:  1986-09-04       Impact factor: 91.245

7.  Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications.

Authors:  S L Hoffman; C N Oster; C V Plowe; G R Woollett; J C Beier; J D Chulay; R A Wirtz; M R Hollingdale; M Mugambi
Journal:  Science       Date:  1987-08-07       Impact factor: 47.728

8.  Anti-sporozoite antibodies induced by natural infection.

Authors:  P Tapchaisri; Y Chomcharn; C Poonthong; A Asavanich; S Limsuwan; O Maleevan; S Tharavanij; T Harinasuta
Journal:  Am J Trop Med Hyg       Date:  1983-11       Impact factor: 2.345

9.  Antibodies to the repetitive epitope of Plasmodium falciparum circumsporozoite protein in a rural Tanzanian community: a longitudinal study of 132 children.

Authors:  G Del Giudice; H D Engers; C Tougne; S S Biro; N Weiss; A S Verdini; A Pessi; A A Degremont; T A Freyvogel; P H Lambert
Journal:  Am J Trop Med Hyg       Date:  1987-03       Impact factor: 2.345

10.  Development of immunity in natural Plasmodium falciparum malaria: antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32).

Authors:  H K Webster; E F Boudreau; L W Pang; B Permpanich; P Sookto; R A Wirtz
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

View more
  4 in total

1.  Interferon-alpha and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks.

Authors:  D Stürchler; G Zimmer; R Berger; H Etlinger; M Fernex; H Matile; M Just
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

Review 2.  Immune responses to sporozoite antigens and their relationship to naturally acquired immunity to malaria.

Authors:  B M Greenwood
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

3.  Differential antibody responses to Plasmodium falciparum and P. vivax circumsporozoite proteins in a human population.

Authors:  T R Burkot; P M Graves; R A Wirtz; B J Brabin; D Battistutta; J A Cattani; R M Maizels; M P Alpers
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

Review 4.  Antibody Correlates of Protection from Clinical Plasmodium falciparum Malaria in an Area of Low and Unstable Malaria Transmission.

Authors:  Karen E S Hamre; Bartholomew N Ondigo; James S Hodges; Sheetij Dutta; Michael Theisen; George Ayodo; Chandy C John
Journal:  Am J Trop Med Hyg       Date:  2020-10-27       Impact factor: 3.707

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.